Third of men with treatment resistant prostate cancer respond to drug that targets gene defect, study findsBMJ 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h5783 (Published 30 October 2015) Cite this as: BMJ 2015;351:h5783
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial